Study of Tocilizumab to Treat Polymyalgia Rheumatica
Completed · Phase 2
Conditions studied: Polymyalgia Rheumatica (PMR)
In brief
This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess the tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients with polymyalgia rheumatica (PMR).
Key facts
- Study ID
- NCT01396317
- Run by
- Hospital for Special Surgery, New York
- People needed
- 10
- Starts
- 2011-04-01
- Expected to finish
- 2016-01-01
- Last updated by the study team
- 2018-01-17
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hospital for Special Surgery — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.